Silverback Therapeutics Inc

NASDAQ:SBTX   3:59:56 PM EDT
36.60
-1.53 (-4.01%)
Earnings Announcements

Silverback Therapeutics Reports Fourth Quarter And Full Year 2020 Financial Results And Recent Corporate Updates

Published: 03/29/2021 21:01 GMT
Silverback Therapeutics Inc (SBTX) - Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates.
Silverback Therapeutics Inc - $386.6 Million in Cash and Cash Equivalents at End of 2020.
Silverback Therapeutics Inc - Qtrly Net Loss per Share Applicable to Common Stockholders, Basic and Diluted $1.37.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.37

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.39

More details on our Analysts Page.